\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ jugular\\ venous\\ distention\\.\ \(0\)\
\-\ lungs\\ clear\\ to\\ auscultation\\.\ \(0\)\
\-\ no\\ pedal\\ edema\\.\ \(0\)\
\-\ elevated\\ brain\\ natriuretic\\ peptide\\ \\(bnp\\)\\ of\\ 1798\\ pg\\/ml\\ \\(normal\\ is\\ 0\\.0\\-100\\.0\\)\\ which\\ has\\ been\\ shown\\ to\\ be\\ elevated\\ in\\ failing\\ and\\ hypertrophied\\ hearts\\ as\\ well\\ as\\ in\\ amyloidosis\\.\ \(0\)\
\-\ igg\\ lambda\\ monoclonal\\ gammopathy\\ with\\ an\\ igg\\ of\\ 1352\\ mg\\/dl\\.\ \(0\)\
\-\ in\\ patients\\ presenting\\ with\\ heart\\ failure\\ and\\ amyloidosis\\ of\\ the\\ heart\\,\\ the\\ average\\ life\\ expectancy\\ is\\ less\\ than\\ one\\ year\\.\\ \\ cardiac\\ transplantation\\ may\\ be\\ considered\\ as\\ a\\ treatment\\ option\\.\ \(0\)\
\-\ dual\\ isotope\\ exercise\\ stress\\ myocardial\\ perfusion\\ scintigraphic\\ images\\ demonstrate\\ reversible\\ perfusion\\ defects\\ in\\ the\\ anterior\\ and\\ inferolateral\\ myocardium\\ consistent\\ with\\ ischemia\\.\\ \\ the\\ left\\ ventricle\\ shows\\ reversible\\ dilatation\\ on\\ the\\ stress\\ images\\.\\ \\ the\\ gated\\ left\\ ventricular\\ ejection\\ fraction\\ on\\ this\\ exam\\ was\\ calculated\\ at\\ 27\\%\\ \\(normal\\ greater\\ than\\ 45\\%\\)\\,\\ and\\ \\ the\\ left\\ ventricle\\ demonstrated\\ global\\ hypokinesis\\.\ \(0\)\
\-\ repeat\\ dual\\ isotope\\ exercise\\ stress\\ myocardial\\ perfusion\\ scintigraphic\\ images\\ obtained\\ two\\ months\\ after\\ the\\ first\\ set\\ do\\ not\\ show\\ any\\ evidence\\ of\\ ischemia\\;\\ however\\,\\ the\\ left\\ ventricular\\ reversible\\ dilatation\\,\\ reduced\\ ejection\\ fraction\\,\\ and\\ global\\ hypokinesis\\ persisted\\.\\ \\ radiotracer\\ uptake\\ around\\ the\\ heart\\ and\\ within\\ the\\ right\\ ventricle\\ is\\ more\\ prominent\\ on\\ this\\ exam\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ technetium\\-99m\\ pyrophosphate\\ scintigraphic\\ images\\ demonstrate\\ diffuse\\ increased\\ myocardial\\ uptake\\ of\\ tc\\-99m\\ pyrophosphate\\.\\ \\ normal\\ radiotracer\\ uptake\\ is\\ present\\ in\\ the\\ ribs\\,\\ sternum\\,\\ and\\ spine\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ ecg\\ demonstrates\\ a\\ general\\ low\\ voltage\\ which\\ is\\ consistent\\ with\\ an\\ infiltrative\\ process\\.\ \(0\)\
\-\ cardiac\\ amyloidosis\ \(2\)\
\-\ myocarditis\ \(4\)\
\-\ pericarditis\ \(16\)\
\-\ cardiomyopathy\ \(24\)\
\-\ amyloidosis\ \(26\)\
\-\ radiation\\ therapy\\ \ \(68\)\
\-\ persistent\\ blood\\ pool\\ activity\\ \\(occurs\\ if\\ images\\ are\\ taken\\ too\\ early\\ before\\ complete\\ clearance\\ from\\ the\\ blood\\ takes\\ place\\)\ \(0\)\
\-\ doxorubicin\\ \\(adriamycin\\ therapy\\)\ \(0\)\
\-\ the\\ patient\\ presented\\ with\\ complaints\\ of\\ dyspnea\\.\\ \\ he\\ underwent\\ a\\ stress\\ echo\\ that\\ revealed\\ an\\ ejection\\ fraction\\ of\\ 60\\%\\,\\ asymmetric\\ septal\\ hypertrophy\\,\\ and\\ evidence\\ of\\ ischemic\\ inferior\\ left\\ ventricular\\ dysfunction\\.\\ \\ he\\ underwent\\ a\\ cardiac\\ catheterization\\ which\\ revealed\\ two\\ critical\\ stenoses\\ in\\ the\\ right\\ coronary\\ artery\\ and\\ circumflex\\ artery\\.\\ \\ these\\ stenoses\\ were\\ stented\\.\\ \\ subsequent\\ stress\\ thallium\\ exam\\ demonstrated\\ continued\\ evidence\\ of\\ inferior\\ ischemia\\ with\\ significantly\\ reduced\\ left\\ ventricular\\ dysfunction\\.\\ \\ a\\ second\\ cardiac\\ catheterization\\ revealed\\ only\\ luminal\\ irregularities\\ with\\ both\\ stents\\ patent\\.\\ \\ the\\ stress\\ thallium\\ was\\ repeated\\ and\\ showed\\ no\\ perfusion\\ abnormalities\\;\\ however\\,\\ left\\ ventricular\\ dilatation\\ was\\ observed\\.\\ \\ a\\ stress\\ echo\\ was\\ then\\ performed\\ which\\ showed\\ mild\\ to\\ moderate\\ global\\ dysfunction\\ and\\ possible\\ inferior\\ wall\\ ischemia\\.\\ \\ the\\ patient\\ returned\\ for\\ follow\\ up\\ and\\ complained\\ of\\ an\\ unintentional\\ weight\\ loss\\ of\\ 30\\ pounds\\,\\ a\\ poor\\ appetite\\,\\ loss\\ of\\ taste\\,\\ and\\ impotence\\.\\ \\ his\\ ekg\\ at\\ that\\ time\\ showed\\ a\\ very\\ low\\ voltage\\ consistent\\ with\\ an\\ infiltrative\\ process\\.\\ \\ a\\ buccal\\ mucosa\\ biopsy\\ was\\ performed\\ which\\ was\\ strongly\\ positive\\ for\\ amyloid\\ deposition\\.\\ \\ a\\ technetium\\ pyrophosphate\\ study\\ was\\ ordered\\ which\\ revealed\\ diffuse\\ cardiac\\ uptake\\ which\\ was\\ consistent\\ with\\ amyloidosis\\.\ \(0\)\
\-\ this\\ patient\\ most\\ likely\\ has\\ the\\ primary\\ idiopathic\\ form\\ of\\ amyloidosis\\ \\(al\\)\\ based\\ on\\ the\\ fact\\ that\\ he\\ has\\ an\\ associated\\ igg\\ lambda\\ monoclonal\\ gammopathy\\ \\.\\ \\ cardiac\\ symptoms\\ are\\ most\\ common\\ in\\ the\\ primary\\ and\\ heredofamilial\\ amyloidoses\\.\\ \\ it\\ is\\ rare\\ to\\ get\\ cardiac\\ symptoms\\ in\\ the\\ secondary\\ \\(aa\\)\\ form\\ of\\ the\\ disease\\.\\ \\ the\\ patient\\â\\€\\™s\\ poor\\ ejection\\ fraction\\,\\ thickened\\ ventricular\\ walls\\ on\\ echocardiography\\,\\ and\\ global\\ ventricular\\ hypokinesis\\ are\\ all\\ consistent\\ with\\ cardiac\\ amyloidosis\\.\\ \\ the\\ low\\ voltage\\ qrs\\ complex\\ on\\ his\\ ecg\\ is\\ consistent\\ with\\ the\\ disease\\ as\\ well\\.\\ \\ recent\\ studies\\ have\\ associated\\ an\\ elevated\\ brain\\ natriuretic\\ peptide\\ level\\ \\(bnp\\)\\ with\\ amyloidosis\\.\\ \\ this\\ patient\\â\\€\\™s\\ bnp\\ level\\ was\\ excessively\\ elevated\\ at\\ \\ 1798\\ \\(normal\\ 0\\-100\\)\\.\\ \\ the\\ tc\\ pyp\\ study\\ showed\\ diffuse\\ uptake\\ of\\ tc\\ pyp\\ in\\ the\\ heart\\ which\\ is\\ further\\ evidence\\ supporting\\ amyloidosis\\.\\ \\ one\\ must\\ remember\\ that\\ diffuse\\ uptake\\ of\\ \\ tc\\ pyp\\ in\\ the\\ heart\\ is\\ a\\ nonspecific\\ finding\\ for\\ amyloidosis\\ and\\ may\\ also\\ be\\ seen\\ with\\ myocarditis\\,\\ pericarditis\\,\\ cardiomyopathies\\,\\ radiation\\ therapy\\,\\ persistent\\ blood\\ pooling\\,\\ and\\ doxorubicin\\ therapy\\.\\ \\ the\\ fact\\ that\\ the\\ patient\\â\\€\\™s\\ symptoms\\ fit\\ with\\ a\\ global\\ process\\ and\\ that\\ his\\ buccal\\ mucosa\\ biopsy\\ was\\ positive\\ for\\ amyloid\\ deposition\\ are\\ yet\\ further\\ evidence\\ confirming\\ a\\ diagnosis\\ of\\ amyloidosis\\.\\ \ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\ victor\\ wl\\,\\ et\\ al\\.\\ amyloidosis\\ of\\ heart\\ and\\ liver\\:\\ comparison\\ of\\ tc\\-99m\\ pyrophosphate\\ and\\ tc\\-99m\\ methylene\\ diphosphonate\\ for\\ detection\\.\\ \\ radiology\\ 1983\\;\\ 148\\:239\\-242\\.\ \(0\)\
\-\ 2\\.\\ christos\\ s\\,\\ et\\ al\\.\\ \\ amyloidosis\\:\\ review\\ and\\ ct\\ manifestations\\.\\ \\ radiographics\\ 2004\\;\\ 24\\:405\\-416\\.\\ \\ \ \(0\)\
\-\ 3\\.\\ thrall\\ jh\\,\\ ziessman\\ ha\\.\\ \\ nuclear\\ medicine\\:\\ the\\ requisites\\.\\ 2nd\\ ed\\.\\ philadelphia\\,\\ pa\\:\\ mosby\\,\\ inc\\.\\ 2001\\:\\ 105\\-107\\.\ \(0\)\
\-\ 4\\.\\ fauci\\ as\\,\\ et\\ al\\.\\ \\ harrison\\â\\€\\™s\\ principles\\ of\\ internal\\ medicine\\.\\ 14th\\ ed\\.\\ new\\ york\\,\\ ny\\:\\ mcgraw\\-hill\\ companies\\,\\ inc\\.\\ 1998\\:\\ 1856\\-1860\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ amyloidosis\\:\\ 0\\.3898807347782017\ \(0\)\
\-\ the\\:\\ 0\\.16825824823799163\ \(0\)\
\-\ cardiac\\:\\ 0\\.1615939722017476\ \(0\)\
\-\ ventricular\\:\\ 0\\.16016919327252224\ \(0\)\
\-\ tc\\:\\ 0\\.157693849774837\ \(0\)\
\-\ global\\:\\ 0\\.15728539838840114\ \(0\)\
\-\ stress\\:\\ 0\\.15720955212683496\ \(0\)\
\-\ pyp\\:\\ 0\\.13050337382733584\ \(0\)\
\-\ fraction\\:\\ 0\\.12915396500839615\ \(0\)\
\-\ pyrophosphate\\:\\ 0\\.12741875376680675\ \(0\)\
\-\ uptake\\:\\ 0\\.1254981599561779\ \(0\)\
\-\ ejection\\:\\ 0\\.1243603506619725\ \(0\)\
\-\ voltage\\:\\ 0\\.12058746800874509\ \(0\)\
\-\ and\\:\\ 0\\.11803800764991385\ \(0\)\
\-\ hypokinesis\\:\\ 0\\.11739525933948367\ \(0\)\
\-\ heart\\:\\ 0\\.11348202882613899\ \(0\)\
\-\ bnp\\:\\ 0\\.11067156219015432\ \(0\)\
\-\ perfusion\\:\\ 0\\.10912947842553737\ \(0\)\
\-\ of\\:\\ 0\\.10646427359436877\ \(0\)\
\-\ which\\:\\ 0\\.09895035137624508\ \(0\)\
\-\ igg\\:\\ 0\\.09619997571107342\ \(0\)\
\-\ was\\:\\ 0\\.09479993000073338\ \(0\)\
\-\ reversible\\:\\ 0\\.09437123903304069\ \(0\)\
\-\ ischemia\\:\\ 0\\.09423535944049505\ \(0\)\
\-\ scintigraphic\\:\\ 0\\.09275000100226466\ \(0\)\
\-\ consistent\\:\\ 0\\.08849567521581027\ \(0\)\
\-\ myocardial\\:\\ 0\\.08800972903031791\ \(0\)\
\-\ natriuretic\\:\\ 0\\.0870022492182239\ \(0\)\
\-\ 1798\\:\\ 0\\.0870022492182239\ \(0\)\
\-\ al\\:\\ 0\\.08645297554637174\ \(0\)\
\-\ gammopathy\\:\\ 0\\.08039164533916339\ \(0\)\
\-\ dysfunction\\:\\ 0\\.07923888442385615\ \(0\)\
\-\ peptide\\:\\ 0\\.07826350622632244\ \(0\)\
\-\ isotope\\:\\ 0\\.07826350622632244\ \(0\)\
\-\ thallium\\:\\ 0\\.07826350622632244\ \(0\)\
\-\ evidence\\:\\ 0\\.0771980683957748\ \(0\)\
\-\ myocarditis\\:\\ 0\\.0750545417596308\ \(0\)\
\-\ with\\:\\ 0\\.07456952018073067\ \(0\)\
\-\ elevated\\:\\ 0\\.0741745064579315\ \(0\)\
\-\ an\\:\\ 0\\.07281234328259022\ \(0\)\
\-\ lambda\\:\\ 0\\.07265773458641897\ \(0\)\
\-\ showed\\:\\ 0\\.0724724965665304\ \(0\)\
\-\ monoclonal\\:\\ 0\\.07165290234726193\ \(0\)\
\-\ revealed\\:\\ 0\\.07134351792019428\ \(0\)\
\-\ that\\:\\ 0\\.07082659245070855\ \(0\)\
\-\ buccal\\:\\ 0\\.07074392101977613\ \(0\)\
\-\ diffuse\\:\\ 0\\.06823483637147963\ \(0\)\
\-\ doxorubicin\\:\\ 0\\.06778594697088972\ \(0\)\
\-\ in\\:\\ 0\\.06766851072230384\ \(0\)\
\-\ is\\:\\ 0\\.06704384690582395\ \(0\)\
\-\ dilatation\\:\\ 0\\.06661575292799791\ \(0\)\
\-\ stenoses\\:\\ 0\\.06659225538339923\ \(0\)\
\-\ technetium\\:\\ 0\\.06604713070735846\ \(0\)\
\-\ pericarditis\\:\\ 0\\.06504229846820142\ \(0\)\
\-\ left\\:\\ 0\\.06495318086204184\ \(0\)\
\-\ ecg\\:\\ 0\\.06457698250419808\ \(0\)\
\-\ et\\:\\ 0\\.06392554763126339\ \(0\)\
\-\ images\\:\\ 0\\.06291252992059326\ \(0\)\
\-\ dual\\:\\ 0\\.06254010806325082\ \(0\)\
\-\ therapy\\:\\ 0\\.06251611004235398\ \(0\)\
\-\ catheterization\\:\\ 0\\.06149866508649184\ \(0\)\
\-\ amyloid\\:\\ 0\\.06149866508649184\ \(0\)\
\-\ inc\\:\\ 0\\.06149866508649184\ \(0\)\
\-\ process\\:\\ 0\\.06120423467747554\ \(0\)\
\-\ ventricle\\:\\ 0\\.060067840916778234\ \(0\)\
\-\ infiltrative\\:\\ 0\\.05574783992139888\ \(0\)\
\-\ inferior\\:\\ 0\\.05551689017140818\ \(0\)\
\-\ deposition\\:\\ 0\\.05488806120743133\ \(0\)\
\-\ as\\:\\ 0\\.054639045140532486\ \(0\)\
\-\ patient\\:\\ 0\\.053083699700914935\ \(0\)\
\-\ mucosa\\:\\ 0\\.05243660009992773\ \(0\)\
\-\ reduced\\:\\ 0\\.0521856096821225\ \(0\)\
\-\ fact\\:\\ 0\\.0521856096821225\ \(0\)\
\-\ exercise\\:\\ 0\\.05124290851243725\ \(0\)\
\-\ echo\\:\\ 0\\.050385064494780946\ \(0\)\
\-\ his\\:\\ 0\\.04949116696808385\ \(0\)\
\-\ on\\:\\ 0\\.0492919243387127\ \(0\)\
\-\ he\\:\\ 0\\.04832319842015474\ \(0\)\
\-\ medicine\\:\\ 0\\.047954135333708174\ \(0\)\
\-\ form\\:\\ 0\\.04756481248439848\ \(0\)\
\-\ radiotracer\\:\\ 0\\.047488819369704845\ \(0\)\
\-\ blood\\:\\ 0\\.047392783308916206\ \(0\)\
\-\ low\\:\\ 0\\.04682510859447873\ \(0\)\
\-\ poor\\:\\ 0\\.04588978967232572\ \(0\)\
\-\ symptoms\\:\\ 0\\.044649364206927944\ \(0\)\
\-\ normal\\:\\ 0\\.04442476464305392\ \(0\)\
\-\ ed\\:\\ 0\\.04352147269336635\ \(0\)\
\-\ hearts\\:\\ 0\\.04350112460911195\ \(0\)\
\-\ heredofamilial\\:\\ 0\\.04350112460911195\ \(0\)\
\-\ amyloidoses\\:\\ 0\\.04350112460911195\ \(0\)\
\-\ qrs\\:\\ 0\\.04350112460911195\ \(0\)\
\-\ excessively\\:\\ 0\\.04350112460911195\ \(0\)\
\-\ cardiomyopathies\\:\\ 0\\.04350112460911195\ \(0\)\
\-\ christos\\:\\ 0\\.04350112460911195\ \(0\)\
\-\ persistent\\:\\ 0\\.041916747713395174\ \(0\)\
\-\ victor\\:\\ 0\\.04156764692092585\ \(0\)\
\-\ fauci\\:\\ 0\\.04156764692092585\ \(0\)\
\-\ companies\\:\\ 0\\.04156764692092585\ \(0\)\
\-\ are\\:\\ 0\\.04128693263770449\ \(0\)\
\-\ for\\:\\ 0\\.04122283353476557\ \(0\)\
\-\ exam\\:\\ 0\\.04107975020102549\ \(0\)\
\-\ 1352\\:\\ 0\\.040195822669581695\ \(0\)\
\-\ impotence\\:\\ 0\\.040195822669581695\ \(0\)\
\-\ wl\\:\\ 0\\.040195822669581695\ \(0\)\
\-\ stented\\:\\ 0\\.03913175311316122\ \(0\)\
\-\ 14th\\:\\ 0\\.03913175311316122\ \(0\)\
\-\ adriamycin\\:\\ 0\\.038262344981395593\ \(0\)\
\-\ methylene\\:\\ 0\\.038262344981395593\ \(0\)\
\-\ harrison\\:\\ 0\\.038262344981395593\ \(0\)\
\-\ biopsy\\:\\ 0\\.03813456698795603\ \(0\)\
\-\ expectancy\\:\\ 0\\.0375272708798154\ \(0\)\
\-\ 1983\\:\\ 0\\.0375272708798154\ \(0\)\
\-\ underwent\\:\\ 0\\.03747657607827546\ \(0\)\
\-\ this\\:\\ 0\\.03738770475305133\ \(0\)\
\-\ has\\:\\ 0\\.03727456155052\ \(0\)\
\-\ inferolateral\\:\\ 0\\.036890520730051446\ \(0\)\
\-\ principles\\:\\ 0\\.036890520730051446\ \(0\)\
\-\ pedal\\:\\ 0\\.036328867293209485\ \(0\)\
\-\ failing\\:\\ 0\\.036328867293209485\ \(0\)\
\-\ circumflex\\:\\ 0\\.036328867293209485\ \(0\)\
\-\ ziessman\\:\\ 0\\.036328867293209485\ \(0\)\
\-\ ny\\:\\ 0\\.036328867293209485\ \(0\)\
\-\ study\\:\\ 0\\.03628288449078497\ \(0\)\
\-\ radiation\\:\\ 0\\.036051951042377565\ \(0\)\
\-\ positive\\:\\ 0\\.03584878651024857\ \(0\)\
\-\ myocardium\\:\\ 0\\.035826451173630966\ \(0\)\
\-\ taste\\:\\ 0\\.035826451173630966\ \(0\)\
\-\ further\\:\\ 0\\.035433590079647984\ \(0\)\
\-\ diphosphonate\\:\\ 0\\.03537196050988806\ \(0\)\
\-\ thrall\\:\\ 0\\.03537196050988806\ \(0\)\
\-\ unintentional\\:\\ 0\\.03495704304186534\ \(0\)\
\-\ supporting\\:\\ 0\\.03422196894028515\ \(0\)\
\-\ pooling\\:\\ 0\\.03422196894028515\ \(0\)\
\-\ brain\\:\\ 0\\.033914689895906104\ \(0\)\
\-\ calculated\\:\\ 0\\.03389297348544486\ \(0\)\
\-\ jh\\:\\ 0\\.03389297348544486\ \(0\)\
\-\ artery\\:\\ 0\\.033787889171376394\ \(0\)\
\-\ gated\\:\\ 0\\.03358521879052119\ \(0\)\
\-\ stents\\:\\ 0\\.03358521879052119\ \(0\)\
\-\ primary\\:\\ 0\\.033451979337036745\ \(0\)\
\-\ demonstrated\\:\\ 0\\.03343462339879164\ \(0\)\
\-\ fit\\:\\ 0\\.033296127691699616\ \(0\)\
\-\ loss\\:\\ 0\\.0331443047378999\ \(0\)\
\-\ be\\:\\ 0\\.03310368657119714\ \(0\)\
\-\ clearance\\:\\ 0\\.03302356535367923\ \(0\)\
\-\ level\\:\\ 0\\.03286256322046662\ \(0\)\
\-\ sternum\\:\\ 0\\.03276574349947319\ \(0\)\
\-\ cardiomyopathy\\:\\ 0\\.03276574349947319\ \(0\)\
\-\ irregularities\\:\\ 0\\.03276574349947319\ \(0\)\
\-\ two\\:\\ 0\\.0323074639355043\ \(0\)\
\-\ however\\:\\ 0\\.03220021847120639\ \(0\)\
\-\ performed\\:\\ 0\\.032184995666005356\ \(0\)\
\-\ remember\\:\\ 0\\.03206665857035781\ \(0\)\
\-\ persisted\\:\\ 0\\.03185468844170169\ \(0\)\
\-\ transplantation\\:\\ 0\\.03165174110233508\ \(0\)\
\-\ ha\\:\\ 0\\.03165174110233508\ \(0\)\
\-\ luminal\\:\\ 0\\.03145707967768023\ \(0\)\
\-\ set\\:\\ 0\\.03127005403162541\ \(0\)\
\-\ one\\:\\ 0\\.03114827440834618\ \(0\)\
\-\ york\\:\\ 0\\.031090087665493125\ \(0\)\
\-\ requisites\\:\\ 0\\.03091666700075489\ \(0\)\
\-\ than\\:\\ 0\\.03083951702154783\ \(0\)\
\-\ at\\:\\ 0\\.030823055800587307\ \(0\)\
\-\ aa\\:\\ 0\\.03074933254324592\ \(0\)\
\-\ hypertrophied\\:\\ 0\\.030587671545914602\ \(0\)\
\-\ echocardiography\\:\\ 0\\.030587671545914602\ \(0\)\
\-\ confirming\\:\\ 0\\.030431311875106837\ \(0\)\
\-\ critical\\:\\ 0\\.029990825752169357\ \(0\)\
\-\ pounds\\:\\ 0\\.029990825752169357\ \(0\)\
\-\ takes\\:\\ 0\\.029587610235336424\ \(0\)\
\-\ get\\:\\ 0\\.029587610235336424\ \(0\)\
\-\ 1998\\:\\ 0\\.02921584729457045\ \(0\)\
\-\ ekg\\:\\ 0\\.029098099516643848\ \(0\)\
\-\ associated\\:\\ 0\\.028674463514798826\ \(0\)\
\-\ pool\\:\\ 0\\.028549386502171432\ \(0\)\
\-\ appetite\\:\\ 0\\.028549386502171432\ \(0\)\
\-\ average\\:\\ 0\\.028346439162804823\ \(0\)\
\-\ detection\\:\\ 0\\.028346439162804823\ \(0\)\
\-\ most\\:\\ 0\\.028312971416043924\ \(0\)\
\-\ demonstrate\\:\\ 0\\.028282614619802627\ \(0\)\
\-\ repeated\\:\\ 0\\.028248115210988592\ \(0\)\
\-\ mosby\\:\\ 0\\.028248115210988592\ \(0\)\
\-\ jugular\\:\\ 0\\.028057348063983252\ \(0\)\
\-\ manifestations\\:\\ 0\\.02787391996069944\ \(0\)\
\-\ coronary\\:\\ 0\\.027526963871756828\ \(0\)\
\-\ yet\\:\\ 0\\.027526963871756828\ \(0\)\
\-\ philadelphia\\:\\ 0\\.027526963871756828\ \(0\)\
\-\ option\\:\\ 0\\.027444030603715665\ \(0\)\
\-\ radiographics\\:\\ 0\\.027444030603715665\ \(0\)\
\-\ may\\:\\ 0\\.027377307761803076\ \(0\)\
\-\ too\\:\\ 0\\.027362515068022338\ \(0\)\
\-\ strongly\\:\\ 0\\.027362515068022338\ \(0\)\
\-\ to\\:\\ 0\\.027201288976930183\ \(0\)\
\-\ ribs\\:\\ 0\\.0266855238126391\ \(0\)\
\-\ no\\:\\ 0\\.02653685748322816\ \(0\)\
\-\ septal\\:\\ 0\\.026479655466922783\ \(0\)\
\-\ distention\\:\\ 0\\.02641296147461872\ \(0\)\
\-\ well\\:\\ 0\\.026342203403803024\ \(0\)\
\-\ complained\\:\\ 0\\.026218300049963866\ \(0\)\
\-\ comparison\\:\\ 0\\.025910545355040195\ \(0\)\
\-\ nuclear\\:\\ 0\\.02573499635162936\ \(0\)\
\-\ 2001\\:\\ 0\\.025677887373038527\ \(0\)\
\-\ hypertrophy\\:\\ 0\\.025621454256218625\ \(0\)\
\-\ 2004\\:\\ 0\\.025621454256218625\ \(0\)\
\-\ significantly\\:\\ 0\\.025565681190990442\ \(0\)\
\-\ returned\\:\\ 0\\.025565681190990442\ \(0\)\
\-\ nonspecific\\:\\ 0\\.025565681190990442\ \(0\)\
\-\ walls\\:\\ 0\\.025510552915529564\ \(0\)\
\-\ auscultation\\:\\ 0\\.025456054691297293\ \(0\)\
\-\ 2nd\\:\\ 0\\.024894401254455332\ \(0\)\
\-\ patent\\:\\ 0\\.024659450152564894\ \(0\)\
\-\ place\\:\\ 0\\.02452384264321131\ \(0\)\
\-\ asymmetric\\:\\ 0\\.024479483786432613\ \(0\)\
\-\ observed\\:\\ 0\\.024221661932226572\ \(0\)\
\-\ ischemic\\:\\ 0\\.024057213128492082\ \(0\)\
\-\ dyspnea\\:\\ 0\\.02393749447113391\ \(0\)\
\-\ ordered\\:\\ 0\\.02389824698442084\ \(0\)\
\-\ repeat\\:\\ 0\\.023859319888927484\ \(0\)\
\-\ defects\\:\\ 0\\.02345086824252836\ \(0\)\
\-\ must\\:\\ 0\\.02331060687445507\ \(0\)\
\-\ idiopathic\\:\\ 0\\.023009335583272228\ \(0\)\
\-\ thickened\\:\\ 0\\.02294489483616286\ \(0\)\
\-\ disease\\:\\ 0\\.022836448989143207\ \(0\)\
\-\ do\\:\\ 0\\.022546006098246505\ \(0\)\
\-\ complaints\\:\\ 0\\.02240105442980985\ \(0\)\
\-\ review\\:\\ 0\\.02240105442980985\ \(0\)\
\-\ life\\:\\ 0\\.022316152316688365\ \(0\)\
\-\ continued\\:\\ 0\\.022288184244040464\ \(0\)\
\-\ 27\\:\\ 0\\.022043589978667982\ \(0\)\
\-\ before\\:\\ 0\\.0219908983627986\ \(0\)\
\-\ general\\:\\ 0\\.021836229364838467\ \(0\)\
\-\ 45\\:\\ 0\\.021810931996666314\ \(0\)\
\-\ radiology\\:\\ 0\\.021785768124461945\ \(0\)\
\-\ taken\\:\\ 0\\.02173583528374431\ \(0\)\
\-\ around\\:\\ 0\\.02171106357755988\ \(0\)\
\-\ references\\:\\ 0\\.0216864198911002\ \(0\)\
\-\ occurs\\:\\ 0\\.021446744184922737\ \(0\)\
\-\ prominent\\:\\ 0\\.021423426081162857\ \(0\)\
\-\ presenting\\:\\ 0\\.021308515877087795\ \(0\)\
\-\ considered\\:\\ 0\\.021196309695039706\ \(0\)\
\-\ shown\\:\\ 0\\.021086683195346557\ \(0\)\
\-\ complex\\:\\ 0\\.020958373856697587\ \(0\)\
\-\ pa\\:\\ 0\\.02087471306669044\ \(0\)\
\-\ failure\\:\\ 0\\.020651938078313038\ \(0\)\
\-\ subsequent\\:\\ 0\\.020592945044890586\ \(0\)\
\-\ rare\\:\\ 0\\.020534672921986644\ \(0\)\
\-\ moderate\\:\\ 0\\.020420222402947538\ \(0\)\
\-\ second\\:\\ 0\\.020364011032400167\ \(0\)\
\-\ 60\\:\\ 0\\.020345420199040655\ \(0\)\
\-\ lungs\\:\\ 0\\.02007491993357859\ \(0\)\
\-\ greater\\:\\ 0\\.020039985398454543\ \(0\)\
\-\ activity\\:\\ 0\\.019970874874037342\ \(0\)\
\-\ studies\\:\\ 0\\.01995375261967411\ \(0\)\
\-\ clear\\:\\ 0\\.019720280823741495\ \(0\)\
\-\ abnormalities\\:\\ 0\\.019704033643741972\ \(0\)\
\-\ based\\:\\ 0\\.019704033643741972\ \(0\)\
\-\ early\\:\\ 0\\.01960769617090335\ \(0\)\
\-\ very\\:\\ 0\\.019513266496736632\ \(0\)\
\-\ venous\\:\\ 0\\.019420670524848537\ \(0\)\
\-\ then\\:\\ 0\\.019255444642530595\ \(0\)\
\-\ obtained\\:\\ 0\\.01924070415871625\ \(0\)\
\-\ complete\\:\\ 0\\.019067283493978016\ \(0\)\
\-\ weight\\:\\ 0\\.01896895954216178\ \(0\)\
\-\ new\\:\\ 0\\.01881843350077572\ \(0\)\
\-\ liver\\:\\ 0\\.018764853805433277\ \(0\)\
\-\ 30\\:\\ 0\\.018556359713415207\ \(0\)\
\-\ less\\:\\ 0\\.01850563005713606\ \(0\)\
\-\ possible\\:\\ 0\\.018430533344214056\ \(0\)\
\-\ recent\\:\\ 0\\.018418131405580258\ \(0\)\
\-\ first\\:\\ 0\\.018356600968428057\ \(0\)\
\-\ internal\\:\\ 0\\.018332209392397825\ \(0\)\
\-\ right\\:\\ 0\\.01803684726305596\ \(0\)\
\-\ spine\\:\\ 0\\.017969273988466254\ \(0\)\
\-\ finding\\:\\ 0\\.017879930996250525\ \(0\)\
\-\ any\\:\\ 0\\.017579788808550528\ \(0\)\
\-\ show\\:\\ 0\\.017268139835977345\ \(0\)\
\-\ only\\:\\ 0\\.016993955820431794\ \(0\)\
\-\ wall\\:\\ 0\\.01654698849674558\ \(0\)\
\-\ likely\\:\\ 0\\.016254945653653464\ \(0\)\
\-\ edema\\:\\ 0\\.01622357354893985\ \(0\)\
\-\ all\\:\\ 0\\.01619240649212697\ \(0\)\
\-\ time\\:\\ 0\\.016123016610561248\ \(0\)\
\-\ secondary\\:\\ 0\\.016123016610561248\ \(0\)\
\-\ shows\\:\\ 0\\.015964928893814366\ \(0\)\
\-\ presented\\:\\ 0\\.015862375635541916\ \(0\)\
\-\ been\\:\\ 0\\.015847903567630196\ \(0\)\
\-\ months\\:\\ 0\\.015833475288190568\ \(0\)\
\-\ if\\:\\ 0\\.015804749040373444\ \(0\)\
\-\ common\\:\\ 0\\.015426367718646632\ \(0\)\
\-\ mild\\:\\ 0\\.015419758510773915\ \(0\)\
\-\ these\\:\\ 0\\.0153606842735781\ \(0\)\
\-\ patients\\:\\ 0\\.015302332920794921\ \(0\)\
\-\ anterior\\:\\ 0\\.015187729582624064\ \(0\)\
\-\ both\\:\\ 0\\.015168893971366088\ \(0\)\
\-\ more\\:\\ 0\\.014936534386956381\ \(0\)\
\-\ increased\\:\\ 0\\.014709279208932858\ \(0\)\
\-\ follow\\:\\ 0\\.014663972048935997\ \(0\)\
\-\ diagnosis\\:\\ 0\\.014101066204282035\ \(0\)\
\-\ were\\:\\ 0\\.014021588652543139\ \(0\)\
\-\ present\\:\\ 0\\.013957974517426036\ \(0\)\
\-\ it\\:\\ 0\\.013924069042926132\ \(0\)\
\-\ demonstrates\\:\\ 0\\.013665739167336051\ \(0\)\
\-\ have\\:\\ 0\\.01358864264615794\ \(0\)\
\-\ up\\:\\ 0\\.013455558397847513\ \(0\)\
\-\ after\\:\\ 0\\.013195894874132514\ \(0\)\
\-\ treatment\\:\\ 0\\.01295751909612266\ \(0\)\
\-\ seen\\:\\ 0\\.012806247228109422\ \(0\)\
\-\ also\\:\\ 0\\.012794807296072939\ \(0\)\
\-\ within\\:\\ 0\\.012528173348660314\ \(0\)\
\-\ from\\:\\ 0\\.010803283650357393\ \(0\)\
\-\ not\\:\\ 0\\.010738506211900617\ \(0\)\
\-\ ct\\:\\ 0\\.010355867469222431\ \(0\)\
\-\ year\\:\\ 0\\.008382967581744864\ \(0\)\
